I NEED A RESPONSE FOR THIS ASSIGNMENT
Great video post. Alcohol is a leading cause of liver disease worldwide. However, the most crucial therapeutic goal is for your client to abstain from alcohol, to improve outcomes of his disease. In addition to abstinence psychosocial and behavioral therapies integrated with medical care could prove beneficial to enhancing clinical outcomes. Cognitive-behavioral therapy would be appropriate for this client. Cognitive-behavioral therapy focuses on identifying triggers and maladaptive behaviors that cause a relapse. The approach encourages coping mechanisms to allow the replacement of compulsive use of alcohol with alcohol-free circumstances. There are pharmacotherapies such as acamprosate, disulfiram, and naltrexone that are approved by the US Food and Drug Administration (FDA) for the treatment of alcohol use disorder. Studies support the efficacy of naltrexone and acamprosate, but not disulfiram, for alcohol use disorder. There are also other pharmacotherapies such as baclofen, gabapentin, ondansetron, topiramate, and varenicline which are FDA approved for other disorders and show promise for alcohol disorder use (Leggio & Lee, 2017). The aim is to focus on patient-centered care to manage his alcohol use disorder and liver disease. To provide holistic care because this client’s addiction has impacted many aspects of his life, therefore you must address all of his needs to be successful this includes his medical care, mental, social, employment, and legal issues in the treatment plan (Crowley, 2015). The PMHNP should continue to use motivational strategies to convey their confidence that the client can accomplish goals and support his optimism, self-confidence, and self-efficacy. The clinician should also promote hope and positive expectations by looking for opportunities to convey their belief in the client and their ability to succeed in their aspirations. Research has shown the therapeutic alliance can influence the client’s outcomes (Barry & Wheeler, 2018).